

Antipsychotic Agents – Antipsychotic Oral / Transdermal Agents

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DS – Maximum Days’ Supply Allowed	PU – Prior Use of Other Medication is Required
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DT – Duration of Therapy Limit	QL – Quantity Limit
BY – Diagnosis Codes Bypass Some Requirements	DX – Diagnosis Code Requirement	RX – Specific Prescription Requirement
CL – Additional Clinical Information is Required	ER – Early Refill	TD – Therapeutic Duplication
CU – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	YQ – Yearly Quantity Limit
DD – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

Antipsychotic Agents – Antipsychotic Oral / Transdermal Agents

POS Edits							
AL – Pimavanserin (Nuplazid®) is limited to use in recipients who are at least 18 years old.							
BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents EXCEPT pimavanserin (Nuplazid®) and molindone when requested for recipients who are younger than 7 years of age.							
CL – Additional clinical information is required for pimavanserin (Nuplazid®).							
DX – Pharmacy claims for all agents must be submitted with an appropriate diagnosis code found at THIS LINK .							
MD – Some agents have a maximum daily dose as listed in the chart below. Requests to override the maximum dose limit should follow THIS CRITERIA .							
Generic – Brand Example*	Age (Years)						
	Younger than 5	5	6-9	10-12	13-15	16-17	18 and older
Aripiprazole – Abilify®	5mg	20mg	20mg	20mg	30mg	30mg	30mg
Aripiprazole – Abilify® MyCite®	0mg	0mg	0mg	0mg	0mg	0mg	30mg
Asenapine – Saphris®	0mg	0mg	0mg	20mg	20mg	20mg	20mg
Asenapine Transdermal - Secuado®	0mg	0mg	0mg	0mg	0mg	0mg	7.6mg
Brexipiprazole – Rexulti®	0mg	0mg	0mg	0mg	4mg	4mg	4mg
Cariprazine – Vraylar®	0mg	0mg	0mg	0mg	0mg	4.5mg	6mg
Clozapine – Clozaril®, FazaClo®, Versacloz®	0mg	0mg	0mg	0mg	0mg	0mg	900mg
Iloperidone – Fanapt®	0mg	0mg	0mg	0mg	0mg	16mg	24mg
Lurasidone – Latuda®	0mg	0mg	0mg	80mg	80mg	80mg	160mg
Lumateperone – Caplyta®	0mg	0mg	0mg	0mg	0mg	0mg	42mg
Olanzapine – Zyprexa®	10mg	20mg	20mg	20mg	30mg	30mg	40mg
Olanzapine/Fluoxetine – Symbyax®	0mg	0mg	0mg	12mg/50mg	12mg/50mg	12mg/50mg	18mg/75mg
Paliperidone – Invega®	3mg	6mg	6mg	6mg	9mg	9mg	12mg
Quetiapine – Seroquel®	100mg	600mg	600mg	600mg	1000mg	1000mg	1200mg
Risperidone – Risperdal®	3mg	6mg	6mg	6mg	8mg	8mg	16mg

Antipsychotic Agents – Antipsychotic Oral / Transdermal Agents

POS Edits							
Ziprasidone – Geodon®	30mg	60mg	60mg	60mg	120mg	120mg	200mg
*Maximum daily dose applies to all oral/transdermal formulations of these agents.							
TD – Oral and transdermal antipsychotic agents are monitored at the pharmacy POS for duplication of therapy with other oral or transdermal antipsychotic agents.							
QL – Selected agents have quantity limits as listed in the chart to the right.	Quantity Limits for Selected Antipsychotic Oral Agents						
	Medication				Quantity Limit		
	<u>Caplyta®</u>				<u>30 capsules per 30 days</u>		
	Cobenfy™				60 capsules per 30 days		
	Latuda® 20mg, 40mg, 60mg & 120mg				30 tablets per 30 days		
	Latuda® 80mg				60 tablets per 30 days		
	Lybalvi™				30 tablets per 30 days		
	Nuplazid® 10mg				30 tablets per 30 days		
	Nuplazid® 34mg				30 capsules per 30 days		
	Rexulti®				30 tablets per 30 days		
	Secuado®				30 patches per 30 days		
	Vraylar®				30 capsules per 30 days		

Antipsychotic Agents – Antipsychotic Oral / Transdermal Agents

Revision / Date	Implementation Date
Created POS Document	February 2020
Added Secuado®, formatting changes / February 2020	May 2020
Modified to apply new age requirement for behavioral health clinical authorization / September 2020	January 2021
Added previous use information for cariprazine (Vraylar®) and lurasidone (Latuda®) / November 2020	January 2021
Changed previous use requirement for cariprazine (Vraylar®) and lurasidone (Latuda®) from 90 days to 365 days / April 2021	April 2021
Added Lybalvi™, added MD for lumateperone (Caplyta®), and added QL for Nuplazid® 10mg tablet / October 2021	April 2022
Modified Rexulti® MD for 13-15 years old, added QL for Latuda®, formatting changes / February 2022	July 2022
Removed previous use requirement for cariprazine (Vraylar®) and lurasidone (Latuda®), policy clarification / November 2022	January 2023
Policy clarification / November 2022	April 2023
Formatting changes / August 2023	October 2023
Removed Vraylar® therapy pack / November 2024	January 2025
Added quantity limits for Rexulti® and Vraylar® / January 2025	June 2025
Added Cobenfy™ / May 2025	July 2025
<u>Added quantity limits for Caplyta® / March 2025</u>	<u>August 2025</u>